Investigating how specific gene mutations affect acute myeloid leukemia and treatment resistance
The role of PTPN11 and NPM1 mutations in acute myeloid leukemia development and therapy resistance
This study is looking at how changes in certain genes might affect the way acute myeloid leukemia (AML) develops and why some people don’t respond to treatments, with the hope of finding better ways to help those patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11191387 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of mutations in the PTPN11 and NPM1 genes in the development of acute myeloid leukemia (AML) and why some patients do not respond to current therapies. By using a specially designed mouse model, researchers will explore how these mutations influence the disease's progression and the body's immune response. The goal is to identify mechanisms of therapy resistance, which could lead to improved treatment strategies for affected patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia, particularly those with PTPN11 and NPM1 mutations.
Not a fit: Patients without acute myeloid leukemia or those whose cancer does not involve PTPN11 or NPM1 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with acute myeloid leukemia who currently have limited options.
How similar studies have performed: Previous research has shown that targeting specific mutations in cancer can lead to significant advancements in treatment, suggesting that this approach may also yield valuable insights.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Fobare, Sydney — Ohio State University
- Study coordinator: Fobare, Sydney
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.